Our Annual Report provides a wide range of information about our global business and how we are working, both within the company and in partnership with others, to meet complex healthcare challenges and deliver life-changing medicines for people worldwide.
Latest Stock Exchange announcements
AstraZeneca and Aspen enter agreement for remaining rights to anaesthetics medicines
AstraZeneca presents superior progression-free survival for Imfinzi in the PACIFIC trial of patients with locally-advanced unresectable lung cancer at ESMO 2017 Congress
AstraZeneca’s Tagrisso shows potential as a new standard of care in 1st-line EGFR-mutated lung cancer at ESMO 2017 Congress
Celgene and AstraZeneca provide update on the FUSION clinical trial programme
Duaklir significantly improves lung function in COPD patients
Our Annual Report provides a wide range of information about our global business.
Answers to frequently asked shareholder questions.
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development